Drug intelligence / Profile preview

fluanisone

Development stage: Discontinued
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous, Intraperitoneal, Oral

Overview

Fluanisone is a typical antipsychotic and sedative of the butyrophenone chemical class. It acts primarily as a dopamine receptor antagonist, particularly at D2 receptors, which underlies its antipsychotic and sedative effects. Fluanisone was used in the treatment of schizophrenia and mania in humans, but is now mainly utilized in veterinary medicine—most notably as part of the combination product fentanyl/fluanisone (Hypnorm) for rodent analgesia and anesthesia during short surgical procedures. Its mechanism also involves enhancement of GABAergic transmission, contributing to CNS depression[3][5][6][8].

Brand names: Hypnorm
Other names: fluanisonefluanisonhaloanisonhaloanisone

Targets

DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on fluanisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluanisone.

Explore the full profile